ICU Medical, Inc. and Pfizer, Inc. have entered into a definitive agreement under which ICU Medical will acquire Hospira Infusion Systems (Pfizer’s global infusion therapy business) for $1 billion. The infusion systems business includes IV pumps, solutions and devices. The union is expected to create a pure-play infusion therapy company, competitive in the U.S. and global market (with direct operations in more than 20 countries), with estimated pro forma combined revenues of about $1.45 billion. It will also “eliminate our single customer concentration issue,” according to Vivek Jain, CEO of ICU Medical.
“The combination of these two businesses is the natural evolution of a productive relationship that began more than 20 years ago when Hospira began integrating ICU Medical’s needlefree technology into their infusion offering globally,” said Jain in a press release.
Market Pulse transactions shown herein are provided as a matter of public record. These transactions have been compiled from press releases, corporate announcements and other public sources to provide an overview of acquisition and merger activities within the healthcare and life sciences sectors.